mRNA 治療市場規模、佔有率和成長分析（按類型、應用、最終用戶和地區）- 產業預測 2025-2032

mRNA 治療市場規模預計在 2023 年達到 110 億美元，並從 2024 年的 117.1 億美元成長到 2032 年的 193.9 億美元，預測期內（2025-2032 年）的複合年成長率為 6.5%。

mRNA 治療市場經歷了顯著成長，尤其是在慢性病治療領域，這主要歸功於 Moderna 和 Pfizer-BioNTech 在 COVID-19 大流行期間成功推出的 mRNA 疫苗。由於這些疫苗在生產和分發過程中的安全性和效率，它們比 DNA 疫苗越來越受到青睞。人體臨床試驗的成功增加了需求，特別是在腫瘤學領域，癌症 mRNA 疫苗的臨床試驗引起了志願者的極大興趣。隨著新的 SARS-CoV-2 變體的出現，對有效的 mRNA 解決方案的需求變得更加迫切。技術進步正在提高 mRNA 產品的穩定性和遞送，顯示該領域具有改變個人化醫療、重塑醫療保健標準和刺激市場擴張的潛力。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 宏觀經濟指標
• 價值鏈分析
• 定價分析
• 監管分析
• 專利分析

mRNA 治療市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• 預防
• 治療

mRNA 治療藥物市場規模（依應用分類）及複合年成長率（2025-2032）

• 市場概況
• 感染疾病
• 瘤
• 罕見遺傳疾病
• 呼吸系統疾病
• 其他

mRNA 治療藥物市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院和診所
• 研究組織
• 其他

mRNA 治療市場規模（按地區分類）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Lonza Group（Switzerland）
• Samsung Biologics（South Korea）
• Fujifilm Diosynth Biotechnologies（Japan）
• Catalent（United States）
• BioNTech（Germany）
• Ionis Pharmaceuticals（United States）
• WuXi Biologics（China）
• CordenPharma（Germany）
• WuXi AppTec（China）
• Boehringer Ingelheim（Germany）
• Samsung Biologics（South Korea）
• WuXi Biologics（China）
• WuXi AppTec（China）
• Boehringer Ingelheim（Germany）
• WuXi Biologics（China）
• WuXi AppTec（China）
• Boehringer Ingelheim（Germany）
• WuXi Biologics（China）
• WuXi AppTec（China）
• Boehringer Ingelheim（Germany）

結論和建議

mRNA Therapeutics Market size was valued at USD 11.0 billion in 2023 and is poised to grow from USD 11.71 billion in 2024 to USD 19.39 billion by 2032, growing at a CAGR of 6.5% during the forecast period (2025-2032).

The mRNA therapeutics market has experienced significant growth, particularly in treating chronic conditions, driven by the successful deployment of mRNA vaccines during the COVID-19 pandemic, primarily by Moderna and Pfizer-BioNTech. These vaccines are increasingly preferred over DNA alternatives due to their safety and efficiency in production and distribution. Their success in human clinical trials has heightened demand, particularly in oncology, where cancer mRNA vaccine trials garnered substantial volunteer interest. As new SARS-CoV-2 variants emerge, the need for effective mRNA solutions becomes more urgent. Advancements in technology are enhancing mRNA product stability and delivery, suggesting a promising future for this sector, which is set to transform personalized medicine and reshape healthcare standards, further fueling market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Mrna Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Mrna Therapeutics Market Segments Analysis

Global mRNA Therapeutics Market is segmented by Type, Application, End-user and region. Based on Type, the market is segmented into Prophylactic and Therapeutic. Based on Application, the market is segmented into Infectious Diseases, Oncology, Rare Genetic Diseases,respiratory diseasesand Others. Based on End-user, the market is segmented into Hospitals & Clinics, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Mrna Therapeutics Market

The rapid advancement of mRNA vaccine technology during the COVID-19 pandemic has significantly propelled the mRNA therapeutics market. This health crisis highlighted mRNA's efficacy as a robust mechanism for addressing infectious diseases, paving the way for its broader application in therapeutics. As a result, mRNA has emerged not only as a crucial defense against viruses but also as a promising platform for developing treatments for various diseases, including cancer and genetic disorders. The momentum gained from pandemic-related research and development is expected to continue driving innovation and investment in the mRNA therapeutics sector, solidifying its position in modern medicine.

Restraints in the Mrna Therapeutics Market

The global mRNA therapeutics market faces several constraints, particularly regarding its production and distribution processes. One significant challenge is the need to scale up mRNA production capacity while ensuring a reliable supply chain. This has been particularly problematic during instances like a global health pandemic, which exacerbates the difficulties of maintaining consistent production levels and distribution efficiency. The complexities of establishing and optimizing these processes hinder market growth and innovation, underscoring the need for improved infrastructure and strategic planning within the mRNA therapeutics landscape to effectively meet increasing demand and overcome logistical challenges.

Market Trends of the Mrna Therapeutics Market

The mRNA therapeutics market is witnessing a significant upward trend, particularly in the development of mRNA cancer vaccines, which offer promising advancements in oncology treatment. As research in this field evolves, pharmaceutical companies are increasingly investing in mRNA technology to create tailored vaccines that stimulate the immune system to target specific cancer cells. This innovation not only enhances the potential for personalized medicine but also showcases the adaptability of mRNA platforms beyond infectious diseases, drawing attention from investors and stakeholders alike. Consequently, the mRNA cancer vaccine segment is poised for substantial growth, driving breakthroughs in cancer therapy and ultimately transforming patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global mRNA Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Prophylactic
• Therapeutic

Global mRNA Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Respiratory Diseases
• Others

Global mRNA Therapeutics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Research Organizations
• Others

Global mRNA Therapeutics Market Size & CAGR (2025-2032)

• North America (Type, Application, End-user)
  • US
  • Canada
• Europe (Type, Application, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CordenPharma (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations